1


                                                                    Exhibit 99.1


CONTACT:                         -OR-           INVESTOR RELATIONS COUNSEL:
Bio-Plexus, Inc.                                The Equity Group Inc.
Jill Phillips  (860) 870-6112                   Devin Sullivan    (212) 836-9608
pressrelease@bio-plexus.com                     www.theequitygroup.com


BIO-PLEXUS SHARES QUOTED ON PINK SHEETS

COMPANY EXPECTS TO EMERGE FROM BANKRUPTCY BY JUNE 30, 2001

         Vernon, CT - (BUSINESS WIRE) May 31, 2001 - BIO-PLEXUS, INC., -- (Pink
Sheets: BPLX) a leader in the design, manufacture and marketing of safety
medical needles, today announced that shares of its common stock are now trading
under the symbol "BPLX."

         Quotes for the Company's common stock may be obtained via the Pink
Sheets at www.pinksheets.com. The Company also announced progress in its
reorganization efforts resulting from its voluntary filing of a petition for
relief under Chapter 11 of the United States Bankruptcy Code. Management expects
to emerge from bankruptcy proceedings by June 30, 2001 as a stronger entity,
with a restructured balance sheet and the necessary capital to fund its future
growth.

         The Pink Sheets is a centralized quotation service that collects and
publishes market maker quotes for OTC securities in real time. It is not an
issuer listing service. In order to buy or sell Pink Sheets securities,
investors must contact a broker/dealer. Companies that trade on the Pink Sheets
are not required to meet the listing requirements of the NASDAQ or other
exchanges. Shares of Bio-Plexus' common stock moved from the OTC Bulletin Board
to the Pink Sheets as a result of the Company's delay in meeting the SEC
reporting obligations for the period ended December 31, 2000. Bio-Plexus expects
that it will move forward in meeting all required reporting obligations when it
emerges from ongoing bankruptcy proceedings.

         John Metz, President and Chief Executive Officer of Bio-Plexus,
commented, "Management is concentrating its efforts on the ongoing bankruptcy
proceedings, the outcome of which will have a material effect on the Company and
its operations. I am happy to report that the proceedings are progressing as
planned and as previously reported we expect to emerge from bankruptcy by the
end of our second quarter. We are continuing to operate in a normal fashion and
appreciate the continued support of our customers, suppliers, employees and
shareholders. We are confident that Bio-Plexus will emerge from this period of
transition as a stronger Company poised for accelerated growth."

   2


         Bio-Plexus, Inc., designs, develops, manufactures and holds U.S. and
international patents on safety medical needles and other products under the
PUNCTUR-GUARD(R), DROP-IT(R), and PUNCTUR-GUARD REVOLUTION(TM) brand names. For
independent evaluations of the PUNCTUR-GUARD(R) blood collection needle, refer
to the Centers for Disease Control (MMWR, January 1997) and ECRI (Health
Devices, June 1998 and October 1999) studies. Accidental needlesticks number
about one million per year in the United States and can result in the
transmission of deadly diseases including HIV and Hepatitis B and C.

         NOTE: THIS PRESS RELEASE CONTAINS FORWARD-LOOKING STATEMENTS WITHIN THE
MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. FORWARD-LOOKING
STATEMENTS ARE IDENTIFIED BY THE USE OF SUCH TERMINOLOGY AS "BELIEVES,"
EXPECTS," "MAY," "WILL," "SHOULD," "ANTICIPATES," "PLANS," "ESTIMATES," AND
"INTENDS" OR DERIVATIONS OR NEGATIVES THEREOF OR COMPARABLE TERMINOLOGY.
ACCORDINGLY, SUCH STATEMENTS INVOLVE RISKS (KNOWN AND UNKNOWN) AND
UNCERTAINTIES. THESE RISKS AND UNCERTAINTIES INCLUDE THE COMPANY'S ABILITY TO
TIMELY AND FULLY COMPLETE ITS PLAN OF REORGANIZATION, WHICH IN TURN WILL DEPEND
ON A MULTITUDE OF FACTORS, INCLUDING THE TIMELY APPROVAL OF THE PLAN BY THE
BANKRUPTCY COURT AND AFFECTED PARTIES, THE AVAILABILITY OF SUFFICIENT CAPITAL TO
FUND THE COMPANY'S OPERATIONS DURING THE BANKRUPTCY PROCEEDINGS AND THE
CONTINUED WILLINGNESS OF THE COMPANY'S CUSTOMERS, VENDORS AND EMPLOYEES TO
MAINTAIN THEIR RELATIONSHIPS WITH THE COMPANY DURING THIS PERIOD. THE COMPANY
UNDERTAKES NO OBLIGATION TO UPDATE OR ADVISE UPON ANY SUCH FORWARD-LOOKING
STATEMENT.